Proof of Concept
Concept of product
Figure 1. The package of product.
Description
The products of this group are produced in the form of reagents, which are stored in a light-proof and sealed way and packaged in standard reagent tubes. In boxes, 15 reagents per box. The outer packing material is a paper box, which can be recycled to ensure recycling. There are four colors of red, yellow, blue, and green in order on the carton, which is also the theme color of our ATCG group. The combination of the four colors not only reflects our spirit of inclusiveness and innovation, but also reflects the plasticity and recombination ability of gene editing technology. In the middle circle of the outer packaging, we will leave out white to mark the product name and team logo. Meanwhile, we will mark a series of information that should be provided by the developer, cooperative supplier, and manufacturer to ensure the transparency and legality of processing, manufacturing, and sales. This product contains the efforts and sweat of our whole team. I hope we can usher in a future as colorful as its color.

• Nonproprietary (Generic) Name: ATCG-1
• Dosage: 1200ul
• Dosage Form: Injection drug dosage form
• Color: colorless
• Optimum shelf life: 12 months at -112 ~ -4℉(-80 ~ -20℃)
The target population of medicine
People who have genetic diseases and hope to be cured, have a relatively high income, can receive new treatment, and can afford the cost.
Matters needing attention
Along with its needed effects, a medicine may cause unwanted effects. Check with your doctor immediately if they occur.
After receiving this treatment:
1. Patients need to stay in the hospital for daily check-ups
2. Don't take too much exercise
3. Eat light meals
4. Receive medication-assisted treatment provided by your doctor
Report to your doctor immediately and seek care if any of the following conditions occur:
1. Headaches and nausea
2. Severe insomnia
3. Poor appetite
4. Difficulty breathing
5. Heart failure
Please do not ignore any minor problems, the consequences of missing the target are very serious, if there are any occurrences of the above problems, please report them to the doctor immediately.
Figure 2. Screenshots of our educational videos.
Viability test and analysis
Due to the risk of off-target caused by the CRISPR gene editing technology, our team began to study the influence of TSD and TIR components on Casposons’ implementation of copy and paste vertex insertion. Firstly, we obtained KAN-TIR and the TSD fragments from the pUC-19 by PCR (Polymerase Chain Reaction), PCR products extraction, and plasmids extraction. Then, we combined Casposons with the target genes, precipitated the mixture with Isopropanol at 37 ° C for 1 minute, and dissolved the sediment in sterile water. In the end, we measure the concentration with accounting measuring instruments, and then conduct a sequencing inspection. The results showed that by adding TSD and TIR elements that can be recognized by Casposons, the plasmid skeleton that can meet the needs of fixed-point insertion can be obtained, so as to realize fixed-point insertion.

Sequencing result of Casposase reaction product
Table 1. In vitro casposons gene-editing system
Figure 3. The sequencing data mapped to the plasmid sequence
To verify whether the long fragment gene with TIR sequence could be inserted into the TSD sequence effectively and correctly, casposase was added for reaction, and the reaction product was recovered for sequencing. Metal bath reaction at 37℃ for 1h; 4uL PK enzyme (PK/ 0.5m EDTA V/V =1:1) was added to each tube, and digested in the metal bath at 37℃ for 30min and inactivated at 95℃ for 10min, recovery of integrated product DH10B (electrical transfer)/sample, SOC medium recovery 1h, the rest evenly blown (Table 1). Based on the result of sequencing, TIR DNA fragments could be integrated by casposase, accurately target TSD sequence for gene editing (Figure 3).
Reference
1. Krupovic, M., Makarova, K.S., Forterre, P. et al. Casposons: a new superfamily of self-synthesizing DNA transposons at the origin of prokaryotic CRISPR-Cas immunity. BMC Biol 12, 36 (2014). https://doi.org/10.1186/1741-7007-12-36